Início › Câncer de Mama › Califórnia › Orange
Ensaios clínicos de Câncer de Mama em Orange, CA
14 estudos para Câncer de Mama estão buscando participantes em locais em Orange e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RecrutandoFase 3
- UC Irvine Medical Center, Orange
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RecrutandoFase 1/2
- University of California Irvine, Orange
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
RecrutandoFase 2
- Community Clinical Trials, Orange
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecrutandoFase 2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecrutandoFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecrutandoFase 3
- UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecrutandoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
E-Mindfulness Approaches for Living After Breast Cancer
RecrutandoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RecrutandoFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecrutandoFase 1/2
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecrutandoFase 3
- Saint Joseph Hospital - Orange, Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
RecrutandoFase 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RecrutandoFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Orange
Ensaios de Câncer de Mama em outras cidades
- New York City, NY134 estudos
- Houston, TX126 estudos
- Boston, MA111 estudos
- Nashville, TN80 estudos
- Los Angeles, CA72 estudos
- Edison, NJ68 estudos
- St. Louis, MO64 estudos
- Durham, NC63 estudos
- Queens, NY63 estudos
- Chicago, IL58 estudos
- Philadelphia, PA56 estudos
- Dallas, TX55 estudos
Outros estudos em Orange
- Câncer de Pulmão de Não Pequenas Células25 estudos
- Câncer Metastático20 estudos
- Câncer Colorretal16 estudos
- Câncer de Ovário16 estudos
- Câncer de Pâncreas15 estudos
- Câncer de Pulmão14 estudos
- Câncer de Próstata14 estudos
- Câncer de Fígado (Carcinoma Hepatocelular)14 estudos
- Melanoma14 estudos
- Leucemia Mieloide Aguda13 estudos
- Câncer (todos os tipos)13 estudos
- Câncer de Estômago13 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.